Chronic Disease

Reports of high-impact chronic disease studies by medical professionals

Thirty minutes of moderate physical activity associated with significantly improved outcomes for patients with...

1. For older adults with overweight or obesity, and metabolic syndrome, replacing 30 minutes of inactive time with moderate to vigorous physical activity was...

Every-other-day dosing of oral rimegepant is effective for preventive treatment of migraines

1. Rimegepant significantly reduced the mean number of migraine days per month between the last 4 weeks of treatment and the observation period compared...

Lansoprazole not effective for the treatment of persistent throat symptoms

1. Lansoprazole was not found to be efficacious in the treatment of persistent throat symptoms. Evidence Rating Level: 1 (Excellent) Persistent throat symptoms are frequently encountered...

Global estimates show one third of the population may benefit from rehabilitation services

 1. Approximately 1 in every 3 people worldwide (2.41 billion) could benefit from rehabilitation services with the Western Pacific region having the greatest need. 2....

Sleep disturbances in older adults linked to higher rates of multimorbidity

1. Moderate to severe sleep disturbances were associated with higher accumulation rates of chronic disease in older adults. 2. Moderate to severe sleep disturbances were...

Cabotegravir plus rilpivirine given every 8 weeks is non-inferior to every 4 weeks for...

1. At week 48, there was a similar proportion of participants with plasma HIV-1 RNA ≥ 50 copies per mL between the 8-week and...

Special Report: Vaccines in Development Part 5: Potential emerging vaccine candidates and other considerations

Section 5: Other Promising Vaccine Candidates and Considerations Messenger RNA (mRNA) vaccines have offered a novel methodology in the context of COVID-19, including the Pfizer/BioNTech1...

COVID-19 susceptibility may be increased in patients with hematological malignancies compared to solid organ...

1. Patients with hematological malignancies were found to be at an increased risk of COVID-19 and were more likely to require admission to the...

Special Report: Vaccines in Development Part 4: Johnson & Johnson vaccine as another frontrunner

Section 4: Johnson & Johnson One of Top 5 COVID-19 Vaccine Finalists The Johnson & Johnson (J&J) Pharmaceutical Research and Development group has focused its...

All-time hits